Clinical Trial Update: Tazarotene 0.045% Lotion for Treating PIE and PIH in Subjects With Acne [Phase 4]

View source ↗

Summary

Phase 4 trial evaluating tazarotene 0.045% lotion for post-inflammatory hyperpigmentation and related skin changes in acne patients; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acne Vulgaris
• Post-inflammatory Hyperpigmentation

Drugs mentioned

• tazarotene 0.045% lotion (tazarotene)

Snippet

Sponsor: Dr. Emmy Graber | Conditions: Acne Vulgaris, Post Inflammatory Hyperpigmentation | Phase 4 | Status: COMPLETED